Oruka Therapeutics clinical trials we track

Check company identity source

Phase 2 6 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs). After: Measure: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs).

Planned enrollment increased by 160 participants

Before: 80 participants (planned). After: 240 participants (planned).

Primary completion date changed

Before: Nov 2028. After: May 2030.

Check registry source